CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-α levels

Summary

Monocytes play a central role in the inflammatory disease atherosclerosis. CD14+CD16+ monocytes are considered proinflammatory monocytes, as they have an increased capacity to produce proinflammatory cytokines, such as TNF-α, and are elevated in various inflammatory diseases. We hypothesized that patients with coronary artery disease (CAD) have increased levels of CD14+CD16+ monocytes, and that CD14+CD16+ monocytes are associated with inflammation markers. We investigated CD14+CD16+ monocytes in 247 patients with CAD and 61 control subjects using flow cytometry. In addition serum concentrations of TNF-α, IL-6, and Hs-CRP were assessed. Patients with CAD had higher levels of CD14+CD16+ monocytes than controls (13.6% versus 11.4%; p<0.001). Logistic regression analysis including quartiles of CD14+CD16+ monocytes showed that CD14+CD16+ monocytes were associated with prevalence of CAD (OR 4.9, 95% CI 2.5–19.1, for subjects in the fourth quartile in comparison to subjects in the first quartile). The association between CD14+CD16+ monocytes and CAD remained independently significant after adjustment for most potential confounders (OR 5.0, 95% CI 1.2-20.0). Serum concentrations of TNF-α were elevated in subjects within the highest quartiles of CD14+CD16+ monocytes (p=0.018). Our study showed that increased numbers of CD14+CD16+ monocytes are associated with coronary atherosclerosis and TNF-α. In accordance, recent animal studies suggest a possibly important role of these monocytes in the development of atherosclerosis.

Keywords

CD14+CD16+ monocytes - TNF-alpha - coronary artery disease

^* Both authors contributed equally to the submitted work

• References

• 1 Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-126.
• 2 Stary HC. et al. A definition of advanced types of atheroslerotic lesions and a histological classification of atherosclerosis. Circulation 1995; 92: 1355-1374.
• 3 Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterisation of a novel monocyte subpopulation in human peripheral blood. Blood 1989; 74: 2527-2534.
• 4 Fingerle G. et al. The novel subset of CD14+ CD16+ monocytes is expanded in sepsis patients. Blood 1993; 82: 3170-3176.
• 5 Nockher WA, Scherberich JE. Expanded CD14+CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Inf Immun 1998; 66: 2782-2790.
• 6 Sester U, Sester M, Heine G. et al. Strong depletion of CD14(+)CD16(+) monocytes during haemodialysis treatment. Nephrol Dial Transplant 2001; 16: 1402-1408.
• 7 Belge KU. et al. The proinflammatory CD14+ CD16+DR++ monocytes are a major source of TNF. J Immunol 2002; 168: 3536-3542.
• 8 Frankenberger M. et al. Differential cytokine expression in human blood monocyte subpopulations: A polymerase chain reaction analysis. Blood 1996; 87: 373-377.
• 9 Lindmark E, Diderholm E, Wallentin L. et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001; 286: 2107-2113.
• 10 Porsch-Oezcueruemez M, Kunz D, Kloer HU. et al. Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease. J Am Coll Cardiol 1999; 34: 1995-2001.
• 11 Koukonnen H, Pentilla K, Kemppainen A. et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001; 33: 37-47.
• 12 Girndt M. Humoral immune responses in uremia and the role of IL-10. Blood Purif 2002; 20: 485-488.
• 13 Skoog T, Dichtl W, Boquist S. et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002; 23: 376-383.
• 14 Ridker PM, Rifai N, Pfeffer M. et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2155.
• 15 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
• 16 Ziegler-Heitbrock HW. Definition of human blood monocytes. J Leukoc Biol 2000; 67: 603-606.
• 17 Muller WA. New mechanisms and pathways for monocyte recruitment. J Exp Med 2001; 194: F47-51.
• 18 Ancuta P. et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
• 19 Umehara H, Bloom E, Okazaki T. et al. Fractalkine and vascular injury. Trends Immunol 2001; 22: 602-607.
• 20 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
• 21 Fong AM, Robinson LA, Steeber DA. et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188: 1413-1419.
• 22 Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
• 23 Combadiere C, Potteaux S, Gao JL. et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003; 107: 1009-1016.
• 24 McDermott DH, Fong AM, Yang Q. et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111: 1241-1250.
• 25 Rothe G, Gabriel H, Kovacs E. et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1996; 16: 1437-1447.
• 26 Rothe G. et al. A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease. Atherosclerosis 1999; 144: 251-261.
• 27 Patino R. et al. Circulating monocytes in patients with diabetes mellitus, arterial disease, and increased CD14 expression. Am J Cardiol 2000; 85: 1288-1291.